The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2014

Filed:

Apr. 13, 2010
Applicants:

Michael J. Pugia, Granger, IN (US);

Rui MA, Mishawaka, IN (US);

Inventors:

Michael J. Pugia, Granger, IN (US);

Rui Ma, Mishawaka, IN (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/26 (2006.01); A61K 38/22 (2006.01); C07K 14/605 (2006.01); A61K 38/28 (2006.01); C07K 14/575 (2006.01); C07K 7/06 (2006.01); C07K 7/02 (2006.01); C07K 7/64 (2006.01); C07K 11/00 (2006.01); C07K 14/47 (2006.01); C07K 14/785 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
G01N 33/574 (2013.01); G01N 33/57415 (2013.01); G01N 2333/575 (2013.01);
Abstract

Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.


Find Patent Forward Citations

Loading…